ESMO WCGIC 2023 | KRAS G12C inhibitors for GI cancer

John Strickler, MD, Duke University, Durham, NC, discusses how KRAS G12C inhibitors other than sotorasib and adagrasib have more recently entered clinical testing. Encouraging single agent data for KRAS G12C inhibitors have been noted in colon and pancreatic cancer settings. The addition of EGFR inhibitors for colorectal cancer has also shown promising results. Future study will focus on other KRAS G12C inhibitors and other inhibitors that target other types of GI cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.